First Patient Dosed in Phase II Clinical Trial for BioInvent's Cardiovascular Drug, BI-204
Trial start triggers US$ 15 million milestone from Genentech
16-Mar-2011 -
BioInvent International AB announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.The Phase II study is a multicenter, ...
Acute Coronary Syndrome
antibodies
cardiovascular diseases
+1